BR0112460A - Método para tratamento de sépsis - Google Patents

Método para tratamento de sépsis

Info

Publication number
BR0112460A
BR0112460A BR0112460-9A BR0112460A BR0112460A BR 0112460 A BR0112460 A BR 0112460A BR 0112460 A BR0112460 A BR 0112460A BR 0112460 A BR0112460 A BR 0112460A
Authority
BR
Brazil
Prior art keywords
sepsis treatment
treatment
sepsis
sepis
prevention
Prior art date
Application number
BR0112460-9A
Other languages
English (en)
Inventor
Andrew Loh
William Louis Macias
Simona Skerjanec
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0112460A publication Critical patent/BR0112460A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MéTODO PARA TRATAMENTO DE SéPSIS". Um novo método de tratamento e/ou prevenção de sépsis.
BR0112460-9A 2000-07-14 2001-06-29 Método para tratamento de sépsis BR0112460A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21892800P 2000-07-14 2000-07-14
US25639800P 2000-12-18 2000-12-18
PCT/US2001/016509 WO2002005796A2 (en) 2000-07-14 2001-06-29 Use of a spla2 inhibitor for the treatment of sepsis

Publications (1)

Publication Number Publication Date
BR0112460A true BR0112460A (pt) 2003-07-22

Family

ID=26913393

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112460-9A BR0112460A (pt) 2000-07-14 2001-06-29 Método para tratamento de sépsis

Country Status (7)

Country Link
EP (1) EP1303262A2 (pt)
JP (1) JP2004503586A (pt)
CN (1) CN1450893A (pt)
AU (1) AU2001272915A1 (pt)
BR (1) BR0112460A (pt)
CA (1) CA2413582A1 (pt)
WO (1) WO2002005796A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5584518B2 (ja) * 2009-05-28 2014-09-03 石原産業株式会社 ジアミノトリフルオロメチルピリジン誘導体を含有する抗ショック剤
CN112022846B (zh) * 2020-09-23 2021-10-08 吕奔 一种吲哚啉衍生物在制备治疗脓毒症药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
PT675110E (pt) * 1994-04-01 2002-11-29 Lilly Co Eli 1h-indole-3-glioxilamidas inibidoras da spla2
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
WO1998008818A1 (en) * 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
AU6229298A (en) * 1997-02-20 1998-09-09 Shionogi & Co., Ltd. Indole dicarboxylic acid derivatives
WO1999021559A1 (en) * 1997-10-27 1999-05-06 Eli Lilly And Company MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
WO1999021545A1 (en) * 1997-10-27 1999-05-06 Eli Lilly And Company ISOPROPYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
AU1279899A (en) * 1997-10-27 1999-05-17 Eli Lilly And Company N,n-diethylglycolamido ester prodrugs of indole spla2 inhibitors
EE200000522A (et) * 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
JP2002505282A (ja) * 1998-03-03 2002-02-19 塩野義製薬株式会社 ホスホリパーゼ阻害剤の［［３−（２−アミノ−１，２−ジオキソエチル）−２−エチル−１−フェニルメチル）−１ｈ−インドール−４−イル］オキシ］酢酸ナトリウムを含む薬学的組成物
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
ID23219A (id) * 1998-04-17 2000-03-30 Lilly Co Eli Trisiklik tersubstitusi
SK16332000A3 (sk) * 1998-05-01 2001-06-11 Eli Lilly And Company Ester ako inhibítor spla2
EP1100493A4 (en) * 1998-08-03 2001-10-24 Lilly Co Eli SPLA 2 INHIBITORS? OF THE INDOLTYPS
CA2338855A1 (en) * 1998-08-03 2000-02-17 Eli Lilly And Company Indole spla2 inhibitors
JP2002542148A (ja) * 1998-12-21 2002-12-10 イーライ・リリー・アンド・カンパニー 敗血症の処置のための組み合わせ療法
JP2002532571A (ja) * 1998-12-22 2002-10-02 イーライ・リリー・アンド・カンパニー 新規ｓＰＬＡ２インヒビター

Also Published As

Publication number Publication date
EP1303262A2 (en) 2003-04-23
CA2413582A1 (en) 2002-01-24
CN1450893A (zh) 2003-10-22
AU2001272915A1 (en) 2002-01-30
JP2004503586A (ja) 2004-02-05
WO2002005796A3 (en) 2002-09-06
WO2002005796A2 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
BR9908280A (pt) Inibidores de enzimas de fosfolipase
BR9909242A (pt) Inibidores de fosfolipase a2
MY129409A (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
BR0317715A (pt) Composições e processos de uso de collajolie
ATE225351T1 (de) Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
TR200100774T2 (tr) Bir aP2 önleyicisinin ve kombinasyonunun kullanıldığı aterosklerozis tedavi yöntemi
MXPA03010327A (es) USO DE OSTEOPONTINA PARA TRATAMIENTO Y/O PREVENCIoN DE ENFERMEDADES NEUROLoGICAS.
BRPI0110506B8 (pt) uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
DK0946166T3 (da) Anvendelse af matrixmetalloproteinaseinhibitorer til fremme af sårheling
AU2001262401A1 (en) Use of ellagic acid as anti-pollution cosmetic agent
MA26486A1 (fr) Aryl- et heteroaryl-thiazolocetohydrazides inhibiteurs de proteases, et compositions pharmaceutiques les contenant .
BR9813996A (pt) 2-arilbenzo[b]tiofenos úteis para o tratamento de sìndrome da privação de estrogênio
BR0108980A (pt) Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
MXPA02011558A (es) Inhibidores de mmp-2/mp-9 novedosos.
ATE299703T1 (de) Mmp-hemmer bei bindegewebserweichung
BR0112460A (pt) Método para tratamento de sépsis
ITMC20020011A1 (it) Metodo e relativo impianto per l'incisione laser di lastre o cilindricalcografici.
DE69930844D1 (de) Inhibitoren von mycobakterien
BR9914722A (pt) Derivados de anticonvulsivo úteis no tratamento de dependência, vìcio e abuso do álcool
DE69838686D1 (de) Tripeptidylpeptidaseinhibitoren
FR2802101B1 (fr) Association de cymemazine et d'un neuroleptique atypique
TR200003084T2 (tr) Paroxetine askorbat
EP1351680B8 (fr) Utilisation de l'anethole-dithiolethione dans la prevention et le traitement de la tenotoxicite induite par un medicament

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired